Cargando…
Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada
BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354805/ https://www.ncbi.nlm.nih.gov/pubmed/34493410 http://dx.doi.org/10.1016/j.vaccine.2021.08.019 |
_version_ | 1783736656364306432 |
---|---|
author | Pépin, Jacques Labbé, Annie-Claude Carignan, Alex Parent, Marie-Elise Yu, Jennifer Grenier, Cynthia Beauchemin, Stéphanie De Wals, Philippe Valiquette, Louis Rousseau, Marie-Claude |
author_facet | Pépin, Jacques Labbé, Annie-Claude Carignan, Alex Parent, Marie-Elise Yu, Jennifer Grenier, Cynthia Beauchemin, Stéphanie De Wals, Philippe Valiquette, Louis Rousseau, Marie-Claude |
author_sort | Pépin, Jacques |
collection | PubMed |
description | BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2. Numerous ecological studies, plagued by methodological deficiencies, revealed a country-level association between BCG use and lower COVID-19 incidence and mortality. We aimed to determine whether BCG administered in early life decreased the risk of SARS-CoV-2 infection in adulthood and the severity of COVID-19. METHODS: This case-control study was conducted in Quebec, Canada. Cases were patients with a positive SARS-CoV-2 nucleic acid amplification test performed at two hospitals between March–October 2020. Controls were identified among patients with non-COVID-19 samples processed by the same microbiology laboratories during the same period. Enrolment was limited to individuals born in Quebec between 1956 and 1976, whose vaccine status was accessible in a computerized registry of 4.2 million BCG vaccinations. RESULTS: We recruited 920 cases and 2123 controls. Fifty-four percent of cases (n = 424) and 53% of controls (n = 1127) had received BCG during childhood (OR: 1.03; 95% CI: 0.89–1.21), while 12% of cases (n = 114) and 11% of controls (n = 235) had received two or more BCG doses (OR: 1.14; 95% CI: 0.88–1.46). After adjusting for age, sex, material deprivation, recruiting hospital and occupation there was no evidence of protection conferred by BCG against SARS-CoV-2 (AOR: 1.01; 95% CI: 0.84–1.21). Among cases, 77 (8.4%) needed hospitalization and 18 (2.0%) died. The vaccinated were as likely as the unvaccinated to require hospitalization (AOR: 1.01, 95% CI: 0.62–1.67) or to die (AOR: 0.85, 95% CI: 0.32–2.39). CONCLUSIONS: BCG does not provide long-term protection against symptomatic COVID-19 or severe forms of the disease. |
format | Online Article Text |
id | pubmed-8354805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Author(s). Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83548052021-08-11 Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada Pépin, Jacques Labbé, Annie-Claude Carignan, Alex Parent, Marie-Elise Yu, Jennifer Grenier, Cynthia Beauchemin, Stéphanie De Wals, Philippe Valiquette, Louis Rousseau, Marie-Claude Vaccine Article BACKGROUND: Early in the coronavirus disease 2019 (COVID-19) pandemic, before severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines became available, it was hypothesized that BCG (Bacillus Calmette–Guérin), which stimulates innate immunity, could provide protection against SARS-CoV-2. Numerous ecological studies, plagued by methodological deficiencies, revealed a country-level association between BCG use and lower COVID-19 incidence and mortality. We aimed to determine whether BCG administered in early life decreased the risk of SARS-CoV-2 infection in adulthood and the severity of COVID-19. METHODS: This case-control study was conducted in Quebec, Canada. Cases were patients with a positive SARS-CoV-2 nucleic acid amplification test performed at two hospitals between March–October 2020. Controls were identified among patients with non-COVID-19 samples processed by the same microbiology laboratories during the same period. Enrolment was limited to individuals born in Quebec between 1956 and 1976, whose vaccine status was accessible in a computerized registry of 4.2 million BCG vaccinations. RESULTS: We recruited 920 cases and 2123 controls. Fifty-four percent of cases (n = 424) and 53% of controls (n = 1127) had received BCG during childhood (OR: 1.03; 95% CI: 0.89–1.21), while 12% of cases (n = 114) and 11% of controls (n = 235) had received two or more BCG doses (OR: 1.14; 95% CI: 0.88–1.46). After adjusting for age, sex, material deprivation, recruiting hospital and occupation there was no evidence of protection conferred by BCG against SARS-CoV-2 (AOR: 1.01; 95% CI: 0.84–1.21). Among cases, 77 (8.4%) needed hospitalization and 18 (2.0%) died. The vaccinated were as likely as the unvaccinated to require hospitalization (AOR: 1.01, 95% CI: 0.62–1.67) or to die (AOR: 0.85, 95% CI: 0.32–2.39). CONCLUSIONS: BCG does not provide long-term protection against symptomatic COVID-19 or severe forms of the disease. The Author(s). Published by Elsevier Ltd. 2021-12-08 2021-08-11 /pmc/articles/PMC8354805/ /pubmed/34493410 http://dx.doi.org/10.1016/j.vaccine.2021.08.019 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Pépin, Jacques Labbé, Annie-Claude Carignan, Alex Parent, Marie-Elise Yu, Jennifer Grenier, Cynthia Beauchemin, Stéphanie De Wals, Philippe Valiquette, Louis Rousseau, Marie-Claude Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title | Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title_full | Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title_fullStr | Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title_full_unstemmed | Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title_short | Does BCG provide long-term protection against SARS-CoV-2 infection? A case–control study in Quebec, Canada |
title_sort | does bcg provide long-term protection against sars-cov-2 infection? a case–control study in quebec, canada |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354805/ https://www.ncbi.nlm.nih.gov/pubmed/34493410 http://dx.doi.org/10.1016/j.vaccine.2021.08.019 |
work_keys_str_mv | AT pepinjacques doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT labbeannieclaude doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT carignanalex doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT parentmarieelise doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT yujennifer doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT greniercynthia doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT beaucheminstephanie doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT dewalsphilippe doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT valiquettelouis doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada AT rousseaumarieclaude doesbcgprovidelongtermprotectionagainstsarscov2infectionacasecontrolstudyinquebeccanada |